CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

MiR Scientific notes the data show that miR Scientific's platform can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%, which translates to AUC of 0.98.

The AuroLase pivotal study follows the successful first-in-human pilot study that enrolled 46 subjects at three U.S. sites. Pandemic related delays to the one-year end of study biopsies for the final subset of feasibility study subjects should be resolved within the next several weeks and, consequently, final results of the feasibility study are expected later this year.

The study will evaluate the performance of the investigational TactiFlex™ Ablation Catheter, Sensor Enabled™ for people whose AFib symptoms are unable to be managed by medication.

"We are thrilled to have had a record number of MolecuLight-based clinical posters and presentations, from so many wound care professionals and settings, be included at the SAWC's Virtual Session", says Anil Amlani, MolecuLight's CEO.

LuViva will be studied to assess its ability to help detect a significant number of the up to 40% to 50% cases missed at the point of biopsy because of limitations in current imaging technology.

The study was led by Dr. Liron Pantanowitz and Dr. Rajiv Dhir, pathologists at UPMC Shadyside Hospital, who provided blinded whole slide images of prostate core needle biopsies for analysis by Ibex's Galen™ Prostate solution.

REACH PVI study prospectively evaluated acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease (PAD) in lower extremity lesions.

The RNS® System has been shown to dramatically reduce seizures and improve quality of life for people living with refractory epilepsy.

Published in the Journal of Pain Research, the study shows that patients using Kaia back pain app reduced pain levels, anxiety, depression, stress, and improved wellbeing and body functionality significantly more compared to standard-of-care treatments.